Boehringer Ingelheim and GoodRx announced a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer’s biosimilar to Humira, at a low cash price available exclusively on GoodRx. This program is a significant step in addressing access and affordability in one of the largest therapeutic categories with a high-cost burden for patients. Beginning immediately, Boehringer and GoodRx are offering prices for both high-concentration and low-concentration citrate-free formulations of Adalimumab-adbm as a pre-filled syringe or autoinjector at an exclusive cost of $550 per two-pack, which represents a 92% discount from the Humira list price.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx Holdings Board Restructure and New Director Induction
- GoodRx price target raised to $9.50 from $7 at Morgan Stanley
- GoodRx Board Revamp: Adam Karol Exits, Simon Patterson Joins
- Under Armour downgraded, Wynn upgraded: Wall Street’s top analyst calls
- GoodRx upgraded to Outperform from Sector Perform at RBC Capital
Questions or Comments about the article? Write to editor@tipranks.com